Home/Pipeline/QX030N

QX030N

Inflammatory Bowel Disease

Phase 1Active

Key Facts

Indication

Inflammatory Bowel Disease

Phase

Phase 1

Status

Active

Company

Qyuns Therapeutics

About Qyuns Therapeutics

Publicly traded biotech developing antibody therapies for autoimmune and allergic diseases with a pipeline targeting IL-4Rα, IL-17A, IL-23, and TSLP pathways.

View full company profile

Therapeutic Areas

Immunology

Other Inflammatory Bowel Disease Drugs

Drug	Company	Phase	Status
DVI-001	Divamics	Preclinical	Approaching PCC selection
DVI-002	Divamics	Preclinical	Lead optimization
Turq-101	Turquoise Biotechnologies	Preclinical	Active
GS-4875	Gilead	Phase 2	Active
Function-based Consortium for IBD	PharmaBiome	Pre-clinical	Active
Galapagos Collaboration	Scipher Medicine	Discovery/Pre-clinical	Active
IBD Subclassification	Bio-Me	Research	Active
Anti-iRhom2 antibodies	SciRhom	Pre-clinical	Active
IBD Multi-omics Dataset	Ovation.io	Commercial	Active
Noa‑001	Noa Therapeutics	Preclinical	Active
Inflectra	EMS	Phase 3	Active
IW-601	ImmuneWalk Therapeutics	Preclinical	Active